As of 2026-03-29, the EV/EBITDA ratio of Ocular Therapeutix Inc (OCUL) is -3.68. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. OCUL's latest enterprise value is 977.84 mil USD. OCUL's TTM EBITDA according to its financial statements is -265.66 mil USD. Dividing these 2 quantities gives us the above OCUL EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 8.0x - 11.0x | 8.9x |
| Forward P/E multiples | 12.3x - 13.9x | 12.5x |
| Fair Price | (11.95) - (10.41) | (10.00) |
| Upside | -258.3% - -237.9% | -232.4% |
| Date | EV/EBITDA |
| 2026-03-26 | -4.11 |
| 2026-03-25 | -4.32 |
| 2026-03-24 | -4.13 |
| 2026-03-23 | -4.13 |
| 2026-03-20 | -4.20 |
| 2026-03-19 | -4.27 |
| 2026-03-18 | -4.45 |
| 2026-03-17 | -4.61 |
| 2026-03-16 | -4.57 |
| 2026-03-13 | -4.67 |
| 2026-03-12 | -4.76 |
| 2026-03-11 | -5.28 |
| 2026-03-10 | -5.58 |
| 2026-03-09 | -5.64 |
| 2026-03-06 | -5.91 |
| 2026-03-05 | -5.96 |
| 2026-03-04 | -6.54 |
| 2026-03-03 | -6.31 |
| 2026-03-02 | -6.49 |
| 2026-02-27 | -4.82 |
| 2026-02-26 | -5.35 |
| 2026-02-25 | -5.28 |
| 2026-02-24 | -4.83 |
| 2026-02-23 | -4.39 |
| 2026-02-20 | -3.87 |
| 2026-02-19 | -3.25 |
| 2026-02-18 | -3.13 |
| 2026-02-17 | -3.22 |
| 2026-02-13 | -4.77 |
| 2026-02-12 | -4.92 |
| 2026-02-11 | -5.00 |
| 2026-02-10 | -4.89 |
| 2026-02-09 | -5.22 |
| 2026-02-06 | -5.00 |
| 2026-02-05 | -4.80 |
| 2026-02-04 | -4.50 |
| 2026-02-03 | -4.47 |
| 2026-02-02 | -4.99 |
| 2026-01-30 | -4.98 |
| 2026-01-29 | -5.65 |
| 2026-01-28 | -5.92 |
| 2026-01-27 | -6.38 |
| 2026-01-26 | -6.42 |
| 2026-01-23 | -5.91 |
| 2026-01-22 | -6.61 |
| 2026-01-21 | -6.85 |
| 2026-01-20 | -6.88 |
| 2026-01-16 | -6.73 |
| 2026-01-15 | -6.74 |
| 2026-01-14 | -6.57 |